$20.96
-0.28 (-1.32%)
Open$20.41
Previous Close$21.24
Day High$22.00
Day Low$19.10
52W High$42.12
52W Low$3.66
Volume—
Avg Volume18.0K
Market Cap45.68M
P/E Ratio—
EPS$-18.93
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-40.9% upside
Current
$20.96
$20.96
Target
$12.39
$12.39
$7.78
$12.39 avg
$16.73
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.91M | 4.59M | 4.05M |
| Net Income | -16,613,133 | -196,564 | -196,089 |
| Profit Margin | -128.7% | -4.3% | -4.8% |
| EBITDA | -16,655,737 | -265,994 | -241,454 |
| Free Cash Flow | — | -252,687 | -239,821 |
| Rev Growth | — | +16.2% | +0.5% |
| Debt/Equity | 0.20 | 1.06 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |